Medherant shortlisted for Royal Society of Chemistry Emerging Technologies competition
Coventry, UK, 12th June 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has been chosen as one of 40 companies shortlisted for the Royal Society of Chemistry (RSC) Eme...
Medherant Appoints Sheryl Caswell to Lead Clinical Development of Products Based on its Revolutionary TEPI Patch®
Coventry, UK, 6th June 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Sheryl Caswell as Head of Clinical Development. Sheryl...
Medherant Appoints Laboratoires Plasto Santé as Transdermal Drug Delivery Patch Manufacturer
Coventry, UK, 8th May 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has appointed Laboratoires Plasto Santé to manufacture its first drug delivery patches. The f...
Medherant Announces Appointment of New Chair
Coventry, UK, 6th February 2017 / Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Dr Ken Cunningham as Chair. Dr Cunningham joins Medherant...
Medherant Ltd. Completes £1.5M Fundraising Round for Transdermal Drug Delivery Platform
Coventry, UK, 27th September 2016 / Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5M, including a direct investment of £650,000 from ...
Mercia Makes Follow-on Investment in Medherant’s Novel Transdermal Technology
Henley-in-Arden, UK, 5th May 2016 / Mercia Fund Management (‘Mercia’), a leading investment business in UK innovation and wholly-owned subsidiary of Mercia Technologies PLC, has committed follow-on capital to Medherant Ltd, a University of W...